Hemant BSc - Poly Medicure Senior Marketing
| POLYMED Stock | 2,692 72.10 2.61% |
Executive
Hemant BSc is Senior Marketing of Poly Medicure Limited
| Age | 65 |
| Address | 232B Okhla Industrial Estate, New Delhi, India, 110020 |
| Phone | 91 11 2632 1838 |
| Web | https://www.polymedicure.com |
Poly Medicure Management Efficiency
The company has return on total asset (ROA) of 0.0882 % which means that it generated a profit of $0.0882 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1501 %, meaning that it generated $0.1501 on every $100 dollars invested by stockholders. Poly Medicure's management efficiency ratios could be used to measure how well Poly Medicure manages its routine affairs as well as how well it operates its assets and liabilities. At present, Poly Medicure's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 489 M, whereas Intangible Assets are forecasted to decline to about 206.7 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Renu Satti | One 97 Communications | N/A | |
| Sarita Pote | Golden Tobacco Limited | N/A | |
| Joseph Chacko | Biofil Chemicals Pharmaceutical | 63 | |
| N Bangera | Golden Tobacco Limited | 74 | |
| Pavan Rajput | Biofil Chemicals Pharmaceutical | 33 | |
| Jessjeet Bhandari | One 97 Communications | 49 | |
| PGDM BTech | Thirumalai Chemicals Limited | 68 | |
| Astha Jain | Uniinfo Telecom Services | N/A | |
| Imtiaz Chougle | Pritish Nandy Communications | N/A | |
| Harshawardhan Sabale | Pritish Nandy Communications | N/A | |
| Ashok Nagarch | DMCC SPECIALITY CHEMICALS | N/A | |
| Vidhi Joshi | Golden Tobacco Limited | N/A | |
| Pawan Rajput | Biofil Chemicals Pharmaceutical | 34 | |
| R Chaudhary | Golden Tobacco Limited | N/A | |
| Anuj Mittal | One 97 Communications | N/A | |
| Sidharth Shakdher | One 97 Communications | N/A | |
| Yatender Verma | Pritish Nandy Communications | N/A | |
| Anisha Mangal | Biofil Chemicals Pharmaceutical | 28 | |
| Rajagopalan | Thirumalai Chemicals Limited | 64 | |
| Akshay Atri | Biofil Chemicals Pharmaceutical | 33 | |
| Santosh Gharat | Pritish Nandy Communications | N/A | |
Management Performance
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0882 |
Poly Medicure Limited Leadership Team
Elected by the shareholders, the Poly Medicure's board of directors comprises two types of representatives: Poly Medicure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Poly. The board's role is to monitor Poly Medicure's management team and ensure that shareholders' interests are well served. Poly Medicure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Poly Medicure's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hemant BSc, Senior Marketing | ||
| Avinash Chandra, Company Officer | ||
| Manish Sardana, President India | ||
| Jugal Baid, Founder Director | ||
| Himanshu Baid, MD CEO | ||
| P Rastogi, Assistant Accounts | ||
| Rishi BSME, Joint Director | ||
| P CA, Assistant Accounts | ||
| Rishi Baid, Joint Director | ||
| Pankaj BE, President RD | ||
| Vishal CA, President Marketing | ||
| Naresh Vijayvergiya, Chief Officer |
Poly Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Poly Medicure a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0882 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 293.22 B | ||||
| Shares Outstanding | 101.33 M | ||||
| Shares Owned By Insiders | 67.30 % | ||||
| Shares Owned By Institutions | 16.60 % | ||||
| Price To Book | 11.74 X | ||||
| Price To Sales | 18.40 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Poly Stock
Poly Medicure financial ratios help investors to determine whether Poly Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Poly with respect to the benefits of owning Poly Medicure security.